DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 1,767 filers reported holding DANAHER CORPORATION in Q4 2020. The put-call ratio across all filers is 0.97 and the average weighting 0.6%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $17,508,049 | +5.9% | 71,091 | +3.2% | 0.13% | +13.6% |
| Q2 2023 | $16,526,382 | -3.9% | 68,858 | +1.0% | 0.12% | -28.9% |
| Q1 2023 | $17,188,216 | +166.1% | 68,196 | +180.2% | 0.17% | +110.1% |
| Q4 2022 | $6,459,134 | -46.6% | 24,335 | -48.0% | 0.08% | -47.7% |
| Q3 2022 | $12,088,000 | +56.4% | 46,801 | +53.5% | 0.15% | +48.0% |
| Q2 2022 | $7,727,000 | -13.5% | 30,481 | +0.1% | 0.10% | +3.0% |
| Q1 2022 | $8,928,000 | -16.8% | 30,439 | -6.7% | 0.10% | -15.4% |
| Q4 2021 | $10,729,000 | +28.0% | 32,611 | +18.5% | 0.12% | 0.0% |
| Q3 2021 | $8,379,000 | +9.5% | 27,524 | -3.4% | 0.12% | +9.3% |
| Q2 2021 | $7,652,000 | +959.8% | 28,502 | +789.6% | 0.11% | +791.7% |
| Q1 2021 | $722,000 | +1.3% | 3,204 | -0.2% | 0.01% | -20.0% |
| Q4 2020 | $713,000 | +31.1% | 3,209 | +27.1% | 0.02% | +7.1% |
| Q3 2020 | $544,000 | +23.1% | 2,525 | +1.1% | 0.01% | +7.7% |
| Q2 2020 | $442,000 | +41.7% | 2,497 | +10.9% | 0.01% | 0.0% |
| Q1 2020 | $312,000 | +17.7% | 2,251 | +30.4% | 0.01% | +18.2% |
| Q4 2019 | $265,000 | +28.6% | 1,726 | +21.1% | 0.01% | +10.0% |
| Q3 2019 | $206,000 | – | 1,425 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
| Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
| Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
| BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
| Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
| Third Point | 2,450,000 | $607,845,000 | 9.22% |
| Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
| Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
| Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
| CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |